Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7338415 | 0.96 | SNCA (0.49) | SNCASIGMAR1PNMTIDO1SLC6A2 | |
| Bromide SCHEMBL1508663 | 0.84 | SNCA (0.47) | SNCASLC6A2SLC6A4SLC6A3PLA2G1B | |
| Bromide SCHEMBL1508860 | 0.84 | SNCA (0.47) | SNCASIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL8424236 | 0.81 | SNCA (0.45) | SNCASIGMAR1PNMTMAPK1HIF1A | |
| Bromide SCHEMBL10721589 | 0.80 | MEN1 (0.47) | SNCAALDH1A1 | |
| Bromide SCHEMBL7084184 | 0.80 | SNCA (0.44) | SNCA | |
| Bromide SCHEMBL10655438 | 0.80 | SNCA (0.47) | SNCAPLA2G1BPOLBATG4BTDP1 | |
| Hydrochloric Acid SCHEMBL9303546 | 0.80 | PNMT (0.49) | SIGMAR1PNMTIDO1SLC6A2SLC6A4 | |
| Bromide SCHEMBL39844 | 0.80 | SNCA (0.73) | SNCASIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL4171166 | 0.79 | SNCA (0.61) | SNCASIGMAR1IDO1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-23 | — | — | US | disclosed |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-06-08 | — | — | US | disclosed |
| WO-2015193921-A1 | AN ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-12-23 | — | — | WO | disclosed |
| EP-2298778-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROÝ2.5¨OCTANE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| EP-1680408-A2 | CCR3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| US-6984637-B2 | Cyclic amine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-0903349-B1 | CCR-3 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005040129-A2 | CCR3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | ROCHE PALO ALTO LLC | 2005-04-28 | — | — | US | disclosed |
| EP-1131291-A1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| US-6140344-A | FOR TREATING PATHOLOGICAL CONDITIONS SUCH AS ASTHMA, RHINITIS, ECZEMA AND PARASITIC INFECTIONS FEATURING TISSUE EOSINOPHILIA | SYNTEX (U.S.A.) INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000029377-A1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-25 | — | — | WO | disclosed |
| US-6011181-A | REDUCING THE LEVEL OF TRI-SUBSTITUTED PHOSPHINE, ARSINE AND/OR STIBINE OXIDE FROM A MIXTURE COMPRISING THE ADDITION OF A METAL SALT TO THE MIXTURE TO FORM A COMPLEX WITH THE OXIDE, AND REMOVING THE COMPLEX | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-04 | — | — | US | disclosed |
| EP-0949238-A1 | SUBSTITUTED PROPIONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0903349-A2 | CCR-3 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-24 | — | — | EP | disclosed |
| EP-0850902-A1 | Process for reducing the level of trisubstituted phosphine, arsine and/or stibine oxide in a mixture | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-01 | — | — | EP | disclosed |
| US-5242945-A | Antiinflammatory | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0508690-A1 | Tetronic and thiotetronic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | TPH1, NAT1, TPH2 | SNCA 581/4885SIGMAR1 22/4885PNMT 9/4885 |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | CCR9, CCR3, CCR1 | SNCA 4450/4885SIGMAR1 589/4885PNMT 3017/4885 |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | TPH1, NAT1, TPH2 | SNCA 581/4885SIGMAR1 22/4885PNMT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.